Beta-Blockers Versus Digoxin to Control Ventricular Rate During Atrial Fibrillation
The recent study of Olshansky et al. (1) investigated the approaches used to control rate, the effectiveness of rate control, and changeovers from one drug class to another in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Comparing the cumulative achievement of adequate ventricular rate control and the time to discontinuation of rate-control therapy, the investigators concluded that beta-blockers were the most effective drugs. We believe the superiority of beta-blockers over other therapeutic options, particularly over digoxin, must be interpreted with caution.
Adequate ventricular rate control was cumulatively obtained in a similar proportion of patients taking beta-blockers alone and digoxin alone (59% vs. 58%, respectively), a result that was confirmed both during rest (68% for both therapies) and with exertion (72% vs. 70%, respectively). Afterwards, the researchers considered beta-blockers more effective, observing that, over time, more patients taking digoxin or a calcium channel blocker were changed to another drug (p Ͻ 0.0001). However, in this comparison, the group of patients using beta-blockers and calcium channel antagonists included those taking digoxin concomitantly, whereas the digoxin group included only individuals using this drug alone. It is possible to observe that, in patients using beta-blockers, the association of digoxin increased the proportion of adequate rate control from 59% to 70%, and this increment may have led to the observed superiority with beta-blocker therapy. Randomized studies have already demonstrated that the association of digoxin with beta-blockers is more effective than betablockers alone in this setting (2, 3) .
In their discussion, the investigators (1) stated that "because no placebo control was used in this trial, it is possible that no medication would have worked as well as digoxin did to control the rate." Because the randomization of the AFFIRM trial was not performed to compare drugs to control ventricular rate, this observation should not be restricted to digoxin. The concept that oral digoxin is efficient in controlling ventricular rate during atrial fibrillation is well accepted (4), despite being supported more by studies that demonstrated the reduction of ventricular rate after the initiation of the therapy (5) than by the sparse number of randomized placebo-controlled trials (6).
